NRBO News and Press, NeuroBo Pharmaceuticals Inc. From 03/30/20

NeuroBo Pharmaceuticals (NASDAQ: NRBO ): FY GAAP EPS of -$4.08. More news on: NeuroBo Pharmaceuticals, Inc., Earnings news and commentary, Consumer stocks news, , Read more ...

BOSTON , March 30, 2020 /PRNewswire/ --  NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financi...

Gainers: Bellerophon Therapeutics (NASDAQ: BLPH )  +144% . More news on: Bellerophon Therapeutics, Inc., Brickell Biotech, Inc., Wanda Sports Group Company Limited, Stocks on the move, , Read more ...